Abstract
Preeclampsia (PE) was first reported thousands of years ago, yet there is still a shortage of biomarkers to determine the severity and type of PE. The importance of the expanded endocannabinoid system, or endocannabinoidome (eCBome), has emerged recently in placental physiology and pathology, though the potential alterations of the eCBome in PE have not been fully explored. Analysis by qRT-PCR using placental samples of normotensive and PE women demonstrate for the first time the presence of ABHD4, GDE1, and DAGLβ in both normotensive and PE placental tissues. Interestingly, NAPE-PLD, FAAH-1, DAGLα, MAGL, and ABHD6 mRNA levels were increased in the placental tissues of PE patients. Quantification in plasma and placental tissues showed a decrease for anandamide (AEA), N-oleoylethanolamine (OEA), and N-docosahexaenoylethanolamine (DHEA) in the placenta, accompanied only by a decrease in plasma levels of AEA. In addition, a strong negative correlation was obtained between OEA and the biomarker of PE, soluble fms-like tyrosine kinase-1. Given the inflammatory nature of PE and the anti-inflammatory role of OEA and DHEA, the decrease in the local levels of these mediators may underlie the inflammatory component of this pathology. Additionally, lower AEA levels in both placenta and plasma may contribute to the atypical alterations of the spiral arteries in PE due to the vasorelaxation effects of AEA. These results add new information to the role of the eCBome members in placental development, while also pointing to a potential role as biomarkers of PE.
Keywords: DHEA, OEA, anandamide, endocannabinoidome, placenta, plasma, preeclampsia
© 2023 The Authors. BioFactors published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
Similar articles
-
Differential expression of endocannabinoid system in normal and preeclamptic placentas: effects on nitric oxide synthesis.Placenta. 2013 Jan;34(1):67-74. doi: 10.1016/j.placenta.2012.10.009. Epub 2012 Nov 1.PMID: 23122699
-
The effect of mifepristone (RU486) on the endocannabinoid system in human plasma and first-trimester trophoblast of women undergoing termination of pregnancy.J Clin Endocrinol Metab. 2014 Mar;99(3):871-80. doi: 10.1210/jc.2013-2922. Epub 2013 Jan 1.PMID: 24423290
-
In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5.PMID: 27503620
-
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.Am J Obstet Gynecol. 2022 Feb;226(2S):S963-S972. doi: 10.1016/j.ajog.2020.10.023. Epub 2021 Mar 9.PMID: 33712272 Review.
-
Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.Biomolecules. 2020 Jun 24;10(6):953. doi: 10.3390/biom10060953.PMID: 32599856 Free PMC article. Review.
References
REFERENCES
-
- Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170:1-7.
- MacDonald TM, Walker SP, Hannan NJ, Tong S, Kaitu’u-Lino TJ. Clinical tools and biomarkers to predict preeclampsia. EBioMedicine. 2022;75:103780.
- Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466-80.
- Anderson UD, Olsson MG, Kristensen KH, Åkerström B, Hansson SR. Review: biochemical markers to predict preeclampsia. Placenta. 2012;33:S42-7.
- Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet. 2019;394:1181-90.
Grant support
LinkOut – more resources
-
Full Text Sources
-
Miscellaneous